Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Marta Szweda; Andrzej Rychlik; Izabella Babińska; Andrzej Pomianowski

doi:10.2478/jvetres-2020-0018

.blurhash-client-img { display: none !important; }

Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology

Journal of Veterinary Research

Volume 64 (2020): Issue 1 (March 2020)

By: Marta Szweda, Andrzej Rychlik, Izabella Babińska and Andrzej Pomianowski

Open Access

|Mar 2020

Abstract

In canine and feline populations, the number of neoplasm cases continues to increase around the world. Attempts are being made in centres of research to identify new biomarkers that speed up and improve the quality of oncological diagnostics and therapy in human and animal tumour patients. Cyclooxygenase-2 (COX-2) is a promising biomarker with increasing relevance to human oncology, but as yet with less application in veterinary oncology. The expression of COX-2 increases significantly during pathological processes involving inflammation, pain or fever. It is also overexpressed in humans presenting various types of tumours and in selected types of tumours in animals, particularly in dogs. This article discusses the expression of COX-2 in canine and feline tumours, the importance of COX-2 as a biomarker with diagnostic, therapeutic, prognostic and predictive relevance in oncology, and the clinical significance of inhibiting COX-2 overexpression in tumours.

References

Anadol E., Yar Saglam A.S., Gultiken N., Karakas K., Alcigir E., Alkan H., Kanca H.: Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopathological features and tumour grade. Acta Vet Hung 2017, 65, 382–393.
Search in Google Scholar Back to article
Araújo M.R., Campos L.C., Damasceno K.A., Gamba C.O., Ferreira E., Cassali G.D.: HER-2, EGFR, Cox-2, and Ki67 expression in lymph node metastasis of canine mammary carcinomas: association with clinical-pathological parameters and overall survival. Res Vet Sci 2016, 106, 121–130.
Search in Google Scholar Back to article
Arber N., Eagle C.J., Spicak J., Rácz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355, 885–895.
Search in Google Scholar Back to article
Arenas C., Peña L., Granados-Soler J.L., Pérez-Alenza M.D.: Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study. Vet Rec 2016, 179, 125.
Search in Google Scholar Back to article
Badowska-Kozakiewicz A.M.: Biological role of cyclooxygenase-2 in veterinary oncology. Życie Wet 2011, 86, 862–864.
Search in Google Scholar Back to article
Bardagí M., Fondevila D., Ferrer L.: Immunohistochemical detection of COX-2 in feline and canine actinic keratoses and cutaneous squamous cell carcinoma. J Comp Pathol 2012, 146, 11–17.
Search in Google Scholar Back to article
Beam S.L., Rassnick K.M., Moore A.S., McDonough S.P.: An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet Pathol 2003, 40, 496–500.
Search in Google Scholar Back to article
Bommer N.X., Hayes A.M., Scase T.J., Gunn-Moore D.A.: Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam. J Feline Med Surg 2012, 14, 527–533.
Search in Google Scholar Back to article
Boria P.A., Murry D.J., Bennett P.F., Glickman N.W., Snyder P.W., Merkel B.L., Schlittler D.L., Mutsaers A.J., Thomas R.M., Knapp D.W.: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004, 224, 388–394.
Search in Google Scholar Back to article
Bronson R.T.: Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982, 43, 2057–2059.
Search in Google Scholar Back to article
Carneiro C.S., de Queiroz G.F., Pinto A.C., Dagli M.L., Matera J.M.: Feline injection site sarcoma: immunohistochemical characteristics. J Feline Med Surg 2019, 21, 314–321.
Search in Google Scholar Back to article
Carvalho M.I., Pires I., Prada J., Raposo T.P., Gregório H., Lobo L., Queiroga F.L.: High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study. Vet Comp Oncol 2017, 15, 619–631.
Search in Google Scholar Back to article
Carvalho S., Stoll A.L., Priestnall S.L., Suarez-Bonnet A., Rassnick K., Lynch S., Schoepper I., Romanelli G., Buracco P., Atherton M., de Merlo E.M., Lara-Garcia A.: Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy. Vet Comp Oncol 2017, 15, 1280–1294.
Search in Google Scholar Back to article
Chandrasekharan N.V., Simmons D.L.: The cyclooxygenases. Genome Biol 2004, 5, 241.
Search in Google Scholar Back to article
De Campos C.B., Damasceno K.A., Gamba C.O., Ribeiro A.M., Machado C.J., Lavalle G.E., Cassali G.D.: Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms. J Feline Med Surg 2016, 18, 1003–1012.
Search in Google Scholar Back to article
Dempke W., Rie C., Grothey A., Schmoll H.J.: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001, 127, 411–417.
Search in Google Scholar Back to article
Denkert C., Winzer K.J., Muller B.M., Weichert W, Pest S., Kobel M., Kristiansen G., Reles A., Siegert A., Guski H., Hauptmann S.: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003, 97, 2978–2987.
Search in Google Scholar Back to article
DiBernardi L., Doré M., Davis J.A., Owens J.G., Mohammed S.I., Guptill C.F., Knapp D.W.: Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007, 76, 245–250.
Search in Google Scholar Back to article
Doré M.: Cyclooxygenase-2 expression in animal cancers. Vet Pathol 2011, 48, 254–265.
Search in Google Scholar Back to article
Doré M., Lanthier I., Sirois J.: Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003, 40, 207–212.
Search in Google Scholar Back to article
Gandhi J., Khera L., Gaur N., Paul C., Kaul R.: Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis. Front Microbiol 2017, 8, 538.
Search in Google Scholar Back to article
Greenhough A., Smartt H.J.M., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A.: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30, 377–386.
Search in Google Scholar Back to article
Gregório H., Raposo T., Queiroga F.L., Pires I., Pena L., Prada J.: High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival. Vet Comp Oncol 2017, 15, 1382–1392.
Search in Google Scholar Back to article
Harris R.E.: Cyclooxygenase-2 (Cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacol 2009, 17, 55–67.
Search in Google Scholar Back to article
Heller D.A., Clifford C.A., Goldschmidt M.H., Holt D.E., Shofer A., Smith A., Sorenmo K.U.: Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol 2005, 42, 776-780.
Search in Google Scholar Back to article
Iturriaga M.P., Oaredes R., Arias J.I., Torres C.G.: Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett 2017, 14, 2198–2206.
Search in Google Scholar Back to article
Kandefer-Gola M., Nowak M., Dzimira S., Janus I., Ciaputa R., Madej J.A.: COX-2 and mPGES-1 expression in canine mast cell tumour. Med Weter 2015, 71, 345–348.
Search in Google Scholar Back to article
Kankuri-Tammilehto M.K., Soderstrom K.O., Pelliniemi T.T., Vahlberg T., Pyrhonen S.O., Salminen E.K.: Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 2010, 30, 3023–3030.
Search in Google Scholar Back to article
Kardosh A., Wang W., Uddin J., Petasis N.A., Hofman F.M., Chen T.C., Schonthal A.H.: Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt’s lymphoma in vitro and in vivo Cancer Biol Ther 2005, 4, 571–582.
Search in Google Scholar Back to article
Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001, 7, 861–867.
Search in Google Scholar Back to article
King J.N., Arnaud J.P., Goldenthal E.I., Gruet P., Jung M., Seewald W., Lees P.: Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. J Vet Pharmacol Ther 2011, 34, 298–311.
Search in Google Scholar Back to article
King J.N., Hotz R., Reagan E.L., Roth D.R., Seewald W., Lees P.: Safety of oral robenacoxib in the cat. J Vet Pharmacol Ther 2012, 35, 290–300.
Search in Google Scholar Back to article
Knapp D.W., Glickman N.W., Widmer W.R., DeNicola D.B., Adams L.G., Kuczek T., Bonney P.L., DeGortari A.E., Han C., Glickman L.T.: Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000, 46, 221–226.
Search in Google Scholar Back to article
Liao Z., Milas L., Komaki R., Stevens C., Cox J.D.: Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 2003, 26, 85–91.
Search in Google Scholar Back to article
Magi G.E., Mari S., Renzoni G., Rossi G.: Immunohistochemical expression of COX-2 in feline injection site sarcoma. Vet Pathol 2010, 4, 340.
Search in Google Scholar Back to article
Mehta S., Shelling A., Muthukaruppan A., Lasham A., Blenkiron C., Laking G., Print C.: Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010, 2, 125–148.
Search in Google Scholar Back to article
Millanta F., Andreani G., Rocchigiani G., Lorenzi D., Poli A.: Correlation between cyclo-oxygenase-2 and vascular endothelial growth factor expression in canine and feline squamous cell carcinomas. J Comp Pathol 2016, 154, 297–303.
Search in Google Scholar Back to article
Millanta F., Asproni P., Canale A., Citi S., Poli A.: COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Vet Comp Oncol 2016, 14, 270–280.
Search in Google Scholar Back to article
Millanta F., Citi S., Della Santa D., Porciani M., Poli A.: COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006, 98, 115–120.
Search in Google Scholar Back to article
Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., Mutsaers A.J., Snyder P.W., Widmer W.R., DeGortari A.E., Bonney P.L., Knapp D.W.: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002, 62, 356–358.
Search in Google Scholar Back to article
Mohammed S.I., Khan K.N., Sellers R.S., Hayek M.G., DeNicola D.B., Wu L., Bonney P.L., Knapp D.W.: Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004, 70, 479–483.
Search in Google Scholar Back to article
Nasry W.H.S., Jones K., Dirksen W.P., Rosol T.J., Rodriguez-Lecompte J.C., Martin C.K.: CD147 and cyclooxygenase expression in feline oral squamous cell carcinoma. Vet Sci 2018, 5, 72.
Search in Google Scholar Back to article
Nóbrega D.F., Sehaber V.F., Madureira R., Bracarense A.P.F.R.L.: Canine cutaneous haemangiosarcoma: biomarkers and survival. J Comp Pathol 2019, 166, 87–96.
Search in Google Scholar Back to article
Nowak M., Madej J.A., Dzięgiel P.: Immunohistochemical localization of COX-2 in cells of mammary adenocarcinomas in bitches as related to tumour malignancy grade. Bull Vet Inst Pulawy 2005, 49, 433–437.
Search in Google Scholar Back to article
Pang L.Y., Argyle S.A., Kamida A., O’Neill Morrison K., Argyle D.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil^TM has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2014, 10, 465.
Search in Google Scholar Back to article
Pestili de Almeida E.M., Piché C., Sirois J., Doré M.: Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001, 49, 867–875.
Search in Google Scholar Back to article
Queiroga F.L., Perez-Alenza M.D., Silvan G., Pena L., Lopes C., Illera J.C.: Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Res 2005, 25, 4269–4276.
Search in Google Scholar Back to article
Queiroga F.L., Pires I., Lobo L., Lopes C.S.: The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Res Vet Sci 2010, 88, 441–445.
Search in Google Scholar Back to article
Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., Yoder B.J., Budd G.T., Nielsen T.O., Hicks D.G., Estopinal N.C., Ross D.T.: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24, 3039–3047.
Search in Google Scholar Back to article
Rizzo M.T.: Cyclooxygenase-2 in oncogenesis. Clin Chem Acta 2011, 412, 671–687.
Search in Google Scholar Back to article
Samarini F., de la Fuente C., Parodi A., Mandara M.T., Pumarola M., Anor S.: Immunohistochemical expression of cyclooxygenase-2 (COX-2) is not associated with tumor grade in feline meningiomas. Vet J 2018, 241, 20–23.
Search in Google Scholar Back to article
Santelices Iglesias O.A., Wright C., Duchene A.G., Risso M.A., Risso P., Zanuzzi C.N., Nishida F., Lavid A., Confente F., Díaz M., Portiansky E.L., Gimeno E.J., Barbeito C.G.: Association between degree of anaplasia and degree of inflammation with the expression of COX-2 in feline injection site sarcomas. J Comp Pathol 2018, 165, 45–51.
Search in Google Scholar Back to article
Sayasith K., Sirois J., Doré M.: Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Vet Pathol 2009, 46, 423–429.
Search in Google Scholar Back to article
Schmidt B.R., Glickman N.W., DeNicola D.B., de Gortari A.E., Knapp D.W.: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001, 218, 1783–1786.
Search in Google Scholar Back to article
Sorenmo K.U., Goldschmidt M., Shofer F.S., Goldkamp C., Ferracone J.: Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004, 2, 13–23.
Search in Google Scholar Back to article
Sparger E.E., Murphy B.G., Kamal F.M., Arzi B., Naydan D., Skouritakis C.T., Cox D.P., Skorupski K.: Investigation of immune cell markers in feline oral squamous cell carcinoma. Vet Immunol Immunopathol. 2018, 202, 52–62.
Search in Google Scholar Back to article
Szweda M., Rychlik A., Babińska I., Pomianowski A.: The significance of cyclooxygenase-2 in oncogenesis. J Vet Res 2019, 63, 215–224.
Search in Google Scholar Back to article
Tamura D., Saito T., Murata K., Kawashima M., Asano R.: Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms. Int J Oncol 2015, 46, 1393–404.
Search in Google Scholar Back to article
Veer van ’t L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530–536.
Search in Google Scholar Back to article
Withrow S.J., MacEwen E.G.: Small Animal Clinical Oncology, 6^th ed., edited by D. Vail, D. Thamm, J. Liptak, Saunders, 2019.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/jvetres-2020-0018 | Journal eISSN: 2450-8608

Journal RSS Feed

Language: English

Page range: 151 - 160

Submitted on: Jun 10, 2019

Accepted on: Feb 25, 2020

Published on: Mar 24, 2020

Published by: National Veterinary Research Institute in Pulawy

In partnership with: Paradigm Publishing Services

Keywords:

dog,

cat,

COX-2,

Related subjects:

Microbiology and virology,

Life sciences, other,

Medicine,

Veterinary medicine

© 2020 Marta Szweda, Andrzej Rychlik, Izabella Babińska, Andrzej Pomianowski, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 64 (2020): Issue 1 (March 2020)